Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?

Iris Lee, Serban Constantinescu, Avrum Gillespie, Abhishek Swami, Mark Birkenbach, Stephen Leech, Patricio Silva, Andreas Karachristos, John A. Daller, Nicole M. Sifontis

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?'. Together they form a unique fingerprint.